Immage Biotherapeutics(OTC) IMMG

Market Cap$200.00

Since IPO (2015)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Immage Biotherapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-02-12

Immage Biotherapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2025-10-06
1 month	+0%	USD 0.00	2025-10-06
3 month	+0%	USD 0.00	2025-10-06
Year to date	+0%	USD 0.00	2025-10-06
1 year	+0%	USD 0.00	2024-12-02
3 year	+0%	USD 0.00	2023-01-17
5 year	-100%	USD 0.02	2021-02-12
Since inception	-100%	USD 0.18	2015-09-14

Immage Biotherapeutics Financials at a Glance

Market Cap

$200.00

Revenue (TTM)

$0.00

Net Income (TTM)

-$114.57K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

10.91 (High)

Dividend

$0.00

Beta (Volatility)

10.91 (High)

Price

$0.00

Volume

500

Open

$0.00

Price

$0.00

Volume

500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

10.91 (High)

Price

$0.00

Volume

500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

IMMG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immage Biotherapeutics

Immage Biotherapeutics Corp. is a biotechnology company focused on developing innovative immunotherapy biologics aimed at treating various types of cancer. Established in 2012 and headquartered in Bethesda, Maryland, the company has undergone significant transformations, including a rebranding from Epicure Charcoal, Inc. in 2015.

Products and Services

Development of immunotherapy biologics for cancer treatment
Research initiatives targeting diverse cancer types
Collaboration with industry partners for advanced therapeutic solutions

Growth Outlook

Potential market expansion in the immunotherapy sector
Increased focus on innovative cancer treatments
Strategic partnerships may enhance research capabilities

Financial Highlights

Recent quarterly net income reported at -44.093 million
Cash and cash equivalents of 53,687 as of February 2017
Current ratio stands at 3.67, indicating strong liquidity

Immage Biotherapeutics Corp. currently operates with limited business activities but has a clear focus on the promising field of cancer immunotherapy. The company’s historical efforts have laid a foundation for future growth, particularly as the demand for innovative cancer treatments continues to rise. The strategic direction towards partnerships and research initiatives may position the company favorably within the biotechnology landscape. Financially, while the company has reported losses, it maintains a solid liquidity position, which could support ongoing research and development efforts. Investors may find the potential for growth in the immunotherapy market an attractive aspect of Immage Biotherapeutics Corp.'s profile.

AI Generated • Jul 15, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Bethesda, MD 20817, US

IMMG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-200.39%

Return on Capital

-90.18%

Return on Assets

-89.05%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$200.00

Shares Outstanding

151.75M

Volume

500

Avg. Volume

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.83M

EBITDA

-$1.82M

Operating Cash Flow

-$274.08K

Capital Expenditure

$0.00

Free Cash Flow

-$274.08K

Cash & ST Invst.

$53.69K

Total Debt

$0.00

Immage Biotherapeutics Performance Analysis

Immage Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2016-05-31	N/A
Q3	2016-08-31	N/A
Q4	2016-11-30	N/A
Q1	2017-02-28	N/A

Immage Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2016-05-31	40.0%
Q3	2016-08-31	-33.3%
Q4	2016-11-30	-2700.0%
Q1	2017-02-28	97.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2017YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$200.00

N/A

Market Cap/Employee

$66.67

N/A

Employees

N/A

Net Income

-$44.09

+99.9%

EBITDA

-$41.96K

+37.6%

Quarterly Fundamentals

Name

Q1 2017YOY CHG

Total Cash

$53.69K

-83.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-89.05%

N/A

Return on Invested Capital

-1.16%

N/A

Free Cash Flow

-$71.95K

-21.5%

Operating Cash Flow

-$71.95K

-21.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CHFIChina Finance, Inc.

CHFIChina Finance, Inc.$0.00+0.00%

BLPFFBLOK Technologies Inc.

BLPFFBLOK Technologies Inc.$0.00+0.00%

CIVXCTR Investments & Consulting, Inc.

CIVXCTR Investments & Consulting, Inc.$0.00+0.00%

XYNHXynergy Holdings, Inc.

XYNHXynergy Holdings, Inc.$0.00+0.00%

AXTGAxis Technologies Group, Inc.

AXTGAxis Technologies Group, Inc.$0.00+0.00%

RNBIRainbow International Corp.

RNBIRainbow International Corp.$0.00+0.00%

TLGNEver Harvest International Group Inc.

TLGNEver Harvest International Group Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About IMMG

What is the current price of Immage Biotherapeutics?

Immage Biotherapeutics is trading at $0.00 per share.

What is the 52-week range for Immage Biotherapeutics?

Over the past 52 weeks, Immage Biotherapeutics has traded between $0.00 and $0.00.

How much debt does Immage Biotherapeutics have?

Immage Biotherapeutics total debt is unavailable.

How much cash does Immage Biotherapeutics have on hand?

Immage Biotherapeutics does not have cash on hand data available.

What is Immage Biotherapeutics’s dividend yield?

Immage Biotherapeutics does not currently have a dividend yield.

Immage Biotherapeutics(OTC) IMMG

Immage Biotherapeutics Financials at a Glance

IMMG News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immage Biotherapeutics

IMMG Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immage Biotherapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMMG

What is the current price of Immage Biotherapeutics?

What is the 52-week range for Immage Biotherapeutics?

How much debt does Immage Biotherapeutics have?

How much cash does Immage Biotherapeutics have on hand?

What is Immage Biotherapeutics’s dividend yield?

Premium Investing Services